Metsera, Inc. Common Stock (MTSR) Stock
MTSR is no longer traded. Metsera, Inc. Common Stock was acquired by Pfizer (PFE) on November 13, 2025.
Each MTSR share was exchanged for $65.60 in cash plus a contingent value right of up to $20.65. Prices on this page are historical; the last trade was November 13, 2025 at $70.50.
See Pfizer (PFE) stock →Metsera, Inc. Common Stock stock price history
MTSR final trading statistics
- Final close
- $70.50
- Final trading day
- Nov 13, 2025
- Market cap at delisting
- $7.43B
- Shares outstanding
- 105.38M
- Final 52-week range
- $12.30 – $83.86
- Avg. volume (final 3 mo.)
- 3,174,240
- All-time high (split-adj.)
- $83.18 · Nov 2025
- All-time low (split-adj.)
- $13.08 · Apr 2025
- Return since IPO
- +291.7%
- Beta
- —
- Book value / share
- $3.21
- Price / book
- 21.98
Metsera, Inc. Common Stock annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$209.1M | -$3.52 |
| FY2023 | $0.00 | -$47.2M | — |
| FY2022 | — | -$813.0K | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
Metsera, Inc. Common Stock stock FAQ
What happened to Metsera, Inc. Common Stock stock?
Metsera, Inc. Common Stock was acquired by Pfizer (PFE) on November 13, 2025. Shareholders received $65.60 in cash plus a contingent value right of up to $20.65 for each share. MTSR stock stopped trading on the Nasdaq, with a final close of $70.50 on November 13, 2025.
What did Metsera, Inc. Common Stock shareholders receive?
Each MTSR share was converted into $65.60 in cash plus a contingent value right of up to $20.65. The deal was valued at up to about $10 billion.
Is MTSR stock still trading?
No. MTSR was delisted from the Nasdaq on November 13, 2025 and no longer trades on a U.S. exchange.
What was the last price of MTSR stock?
MTSR closed at $70.50 on its final trading day, November 13, 2025, for a market value of about $7.43B.
What were Metsera, Inc. Common Stock's revenue and earnings in its last full fiscal year?
Metsera, Inc. Common Stock reported revenue of $0.00 and net income of -$209.1M in fiscal 2024, its last full year as a public company.
When did Metsera, Inc. Common Stock go public?
Metsera, Inc. Common Stock stock began trading on January 31, 2025.